Specialty Drugs to Cost Consumers More Next Year
The patients out of pocket costs for "Specialty Drugs" will increase significantly in 2015.
News
NIH Accelerating Medicines Partnership has awarded 10 US centers grants to study Rheumatoid Arthritis and Lupus
In September 2014, the participating members of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Program funded a research Network to implement the program.
Turmeric vs. Ibuprofen: Which is Better for Arthritis?
Ibuprofen has a corner on the over-the-counter pain market, accounting for one-third of OTC analgesics in the U.S.
Dynamic Duo Takes Out The Cellular Trash
Salk scientists identify how immune cells use two critical receptors to clear dead cells from the body, pointing the way to new autoimmune and cancer therapies.
RoActemra wins EU approval for early RA
Swiss drugmaker Roche Holding AG said on Monday the European Union has approved the use of its drug RoActemra in patients with early-stage rheumatoid arthritis.
The Safety of Restarting Infliximab After a Long Drug-Free Hiatus
Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological
